

# Christoph P Berg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5898177/publications.pdf>

Version: 2024-02-01

25  
papers

1,076  
citations

759055

12  
h-index

610775

24  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1897  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive clinical and virological characterization of three cases of fulminant liver failure owing to <sc>HSV1</sc> primary infection. <i>Liver International</i> , 2022, , .	1.9	2
2	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1&#x2013;3 Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	2.4	12
3	Longitudinal monitoring of laboratory markers characterizes hospitalized and ambulatory COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 14471.	1.6	15
4	Significance and clinical impact of routinely tested urinary ethyl glucuronide after liver transplantation &#x201c; development of a risk score. <i>Transplant International</i> , 2021, 34, 2257-2265.	0.8	0
5	Resistance&#x2013;associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	1.0	12
6	Antibodies to the Muscarinic Acetylcholine Receptor M3 in Primary Biliary Cholangitis Inhibit Receptor Function on Cholangiocytes. <i>Frontiers in Immunology</i> , 2020, 11, 1151.	2.2	5
7	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance&#x2013;associated substitutions. <i>Liver International</i> , 2020, 40, 2660-2671.	1.9	2
8	Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1049-1056.	0.8	7
9	Patterns of Resistance-Associated Substitutions in Patients With&#x2013;Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 976-988.e4.	0.6	132
10	Sulphite oxidase (SO) &#x201c; a mitochondrial autoantigen as target for humoral and cellular immune reactions in primary sclerosing cholangitis. <i>BMC Gastroenterology</i> , 2018, 18, 58.	0.8	2
11	&#x2013;Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor. <i>Frontiers in Immunology</i> , 2018, 9, 1735.	2.2	12
12	Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. <i>PLoS ONE</i> , 2018, 13, e0197544.	1.1	12
13	Hepatitis C &#x201c;late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy. <i>Journal of Hepatology</i> , 2017, 66, 862-863.	1.8	13
14	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
15	Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. <i>World Journal of Gastroenterology</i> , 2016, 22, 8050.	1.4	43
16	First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. <i>Virology Journal</i> , 2015, 12, 37.	1.4	11
17	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. <i>Hepatology International</i> , 2014, 8, 517-526.	1.9	6
18	Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results. <i>PLoS ONE</i> , 2013, 8, e80528.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data. <i>Liver Transplantation</i> , 2012, 18, 1464-1470.	1.3	76
20	Autoantibodies to muscarinic acetylcholine receptors found in patients with primary biliary cirrhosis. <i>BMC Gastroenterology</i> , 2010, 10, 120.	0.8	21
21	Mycoplasma antigens as a possible trigger for the induction of antimitochondrial antibodies in primary biliary cirrhosis. <i>Liver International</i> , 2009, 29, 797-809.	1.9	39
22	Hepatitis C virus core protein induces apoptosis-like caspase independent cell death. <i>Virology Journal</i> , 2009, 6, 213.	1.4	19
23	Demonstration of PDC-E1 subunits as major antigens in the complement-fixing fraction M4 and re-evaluation of PDC-E1-specific antibodies in PBC patients. <i>Liver International</i> , 2006, 26, 846-855.	1.9	8
24	Tributyltin (TBT) induces ultra-rapid caspase activation independent of apoptosome formation in human platelets. <i>Oncogene</i> , 2003, 22, 775-780.	2.6	16
25	Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. <i>Oncogene</i> , 2000, 19, 4563-4573.	2.6	243